Hemophilia B

Primary care physicians can help identify previously unrecognized hemophilia B, respond appropriately to bleeding and procedural risks, reinforce hematology-directed treatment plans, and support patients...

Final phase 3 results assessed 5-year efficacy and safety of etranacogene dezaparvovec in adults with hemophilia B.

In 6-year long-term follow-up of adults with severe or moderately severe hemophilia B, single-dose fidanacogene elaparvovec maintained FIX activity and low treated annualized bleeding rates.

The first of its kind gene therapy treatment has been approved by the FDA for adults with Hemophilia B.